Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells.

@article{Alm2012Transient1N,
  title={Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells.},
  author={Jessica J. Alm and Terhi J. Heino and Teuvo A. Hentunen and H. Kalervo V{\"a}{\"a}n{\"a}nen and Hannu T. Aro},
  journal={Tissue engineering. Part C, Methods},
  year={2012},
  volume={18 9},
  pages={658-66}
}
The development of in vitro culturing techniques for osteoblastic differentiation of human mesenchymal stem cells (hMSC) is important for cell biology research and the development of tissue-engineering applications. Dexamethasone (Dex) is a commonly used supplement, but the optimal use of Dex treatment is still unclear. By adjusting the timing of Dex… CONTINUE READING